Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Strategies to Improve RTS,S-4 Uptake and Integration With Other Child Health Services

11 novembre 2026 aggiornato da: Simon Kariuki, Kenya Medical Research Institute

Investigating Approaches to Increase the Uptake of Malaria Vaccine and Other Childhood Health Interventions in Western Kenya: a Feasibility Study

This study will identify and evaluate innovative approaches to leverage malaria vaccine visits as opportunities to enhance the delivery of other child health services in Rarieda sub-county, Siaya County, Kenya where RTS,S became part of their routine childhood immunization programs in 2019. Using a human-centred design approach, the implementation research will be conducted in two phases.

Phase 1 (Diagnose and Design) will consist of formative research to understand current practices, barriers, and facilitators for childhood health and malaria interventions using the WHO's behavioural and social drivers' framework for immunization. Having identified the barriers and facilitators to uptake, the investigators will prioritize drivers and develop innovations for implementation in collaboration with communities, healthcare workers and managers.

Phase 2 (Implement and Evaluate) will focus on implementing and evaluating the innovations developed in Phase 1. Using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) Framework, the study will assess the extent to which the interventions reach the target population, effectiveness of leveraging the malaria vaccine to increase uptake of other child health interventions, the extent of adoption by key stakeholders, and the fidelity and quality of implementation. The investigators will also explore cost and long-term sustainability.

The study will employ a mixed-methods approach, leveraging quantitative and qualitative data from health facility records, surveys, interviews, and observations.

The investigators will generate evidence on leveraging malaria vaccine visits and activities through: (i) innovative implementation strategies designed to maximize immunizations, child health interventions, and malaria prevention uptake; (ii) community engagement as an approach to optimize vaccine uptake and coverage; (iii) detailed qualitative data on the acceptability, perceptions, and barriers to uptake of vaccines and child health interventions; (iv) approaches to ensure access for zero-dose, under-vaccinated and underserved populations.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

2346

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Siaya, Kenya
        • Ong'ielo Health Centre

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

  1. Primary caregivers of children eligible for malaria vaccination:

    • Inclusion criteria: Primary caregivers (age 18 years or older) of children who are eligible for or have received at least one dose of malaria vaccine
    • Exclusion criteria: Caregivers who are not the primary decision-makers for the child's healthcare or who have resided in the study area for less than 3 months
  2. Healthcare workers involved in immunization services:

    • Inclusion criteria: Clinical officers, nurses, or other healthcare staff directly involved in providing immunization services at the selected health facilities for at least 3 months
    • Exclusion criteria: Healthcare workers not involved in immunization service delivery or who have worked at the facility for less than 3 months
  3. Community health promoters (CHPs):

    • Inclusion criteria: CHPs working in the catchment areas of selected health facilities for at least 6 months
    • Exclusion criteria: CHPs who have not been active in the past 3 months
  4. Community members and leaders:

    • Inclusion criteria: community members and leaders willing to share their views on malaria vaccine barriers and facilitators, and approaches to improve uptake.
    • Exclusion criteria: Community members not willing to participate in the study
  5. Health facility managers and sub-county/county/national health officials:

    • Inclusion criteria: Health facility in-charges, sub-county or county EPI coordinators, and other relevant health officials overseeing immunization services across MoH hierarchy
    • Exclusion criteria: Officials who have been in their current position for less than 3 months

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: ITN - Provision of ITNs at RTS,S-4 visit

Leverage malaria vaccine to improve ITN access and use by providing ITNs at the 4th malaria dose visit, as well as vitamin A, deworming, MR2 and other missing vaccines

- At RTS,S-4 visit, health workers (HW) screen children for missing vaccinations and health services - HW provide catch-up vaccinations and services

Sperimentale: CHP - CHP identify and refer under-vaccinated children to health facility

Using malaria vaccine as an entry point, CHPs systematically identified under-vaccinated children during routine household visits and referred them to health facilities (HF), integrating immunization tracking into routine community activities.

  • CHP screen households for under-vaccinated children
  • CHP Provide referral for immunization
  • HW vaccinate referred children
  • HW provide catch-up vaccinations and services
  • CHP follow up on referral completion
Sperimentale: SMS - Enhanced defaulter tracing with use of mobile technology

Facility-community linkages were strengthened through CHP engagement and mobile phone-based reminders, including SMS notifications and defaulter tracing

  • HF diaries to record expected children on each date
  • HW record phone contacts in diaries to remind caregivers about visits (SMS or calls)
  • If caregivers cannot be reached, HW share contacts by SMS/WhatsApp with CHPs to trace defaulters at the house and provide referrals
  • HW screen & provide catch-up vaccinations & services
Sperimentale: SS - Strengthening immunization systems, health services, and interdepartmental collaboration

Multi-component intervention: 1) strengthening immunizations and health services through interdepartmental collaboration; 2) improving vaccine visit awareness, preparedness, and defaulter tracing; and 3) targeted monthly community outreaches, with CHPs mobilizing caregivers of children due or overdue for vaccination.

  • Screening children for vaccination status at triage
  • HW use colored ink to better visualize return dates in home-based records
  • HW Screen & provide catch-up vaccinations & services
  • CHPs trace defaulters, provide & follow up on referrals
  • HF diaries to record expected children on each date
  • HF conduct targeted community outreaches
  • CHP mobilize defaulters for scheduled outreaches

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Reach
Lasso di tempo: Three months

Vaccine coverage (%) in target populations and characteristics of vaccinated populations reached through study interventions

Three months
Effectiveness
Lasso di tempo: Three months

Percentage increase in primary (dose 1-3) and booster (4th) doses post-interventions in age-eligible children

Three months
Adoption
Lasso di tempo: Three months

Proportion of RTS,S vaccines provided concurrently with other vaccines/services.

Three months
Implementation
Lasso di tempo: Three months

Perceived feasibility of interventions by health workers, caregivers, and community. A semi-structured interview guide will be used to assess implementation experiences.

Three months
Maintenance
Lasso di tempo: Three months

Drivers of maintenance of interventions. A semi-structured interview guide will be used to elicit what it would take to continue implementing interventions beyond the study period.

Three months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Simon Kariuki, PhD, Kenya Medical Research Institute
  • Investigatore principale: Nelli Westercamp, PhD, Centres for Disease Control and Prevention

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 luglio 2025

Completamento primario (Effettivo)

4 dicembre 2025

Completamento dello studio (Effettivo)

4 dicembre 2025

Date di iscrizione allo studio

Primo inviato

22 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Only aggregated data is required for reports and manuscripts.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi